
















Variable		N	Hazard ratio	p	
age_at_diagnosis_days		488		1.00 (1.00, 1.00)	0.002
reported_gender	Female	219		Reference	
	Male	269		0.98 (0.79, 1.21)	0.836
2021_WHO_Classification	Pediatric-type diffuse low-grade gliomas	43		Reference	
	Diffuse astrocytoma, MYB- or MYBL1-altered	7		1.47 (0.59, 3.67)	0.404
	Diffuse low-grade glioma, MAPK pathway-altered	339		1.16 (0.77, 1.75)	0.467
	Ganglioglioma	28		1.39 (0.78, 2.47)	0.264
	Glioneuronal and neuronal tumors	3		2.03 (0.47, 8.75)	0.342
	Myxoid glioneuronal tumor	3		3.20 (0.90, 11.33)	0.072
	Pilocytic astrocytoma	44		1.16 (0.69, 1.95)	0.580
	Pleomorphic xanthoastrocytoma	3		2.53 (0.76, 8.48)	0.132
	Subependymal giant cell astrocytoma	18		0.62 (0.25, 1.50)	0.288
clusterID	3	137		Reference	
	1	188		0.95 (0.72, 1.26)	0.721
	2	163		1.50 (1.11, 2.02)	0.008
			0.5 1 2 5 10 20 50		